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One of the fundamental steps toward malaria control is the 
use of antimalarial drugs. The success of antimalarial treat-
ment can be affected by the presence of drug-resistant pop-
ulations of Plasmodium falciparum. To assess resistance, 
we used molecular methods to examine 351 P. falciparum 
isolates collected from 4 sentinel sites in Mozambique for 
K13, pfmdr1, pfcrt, and pfdhps polymorphisms and for plas-
mepsin2 (pfpm2) and pfmdr1 copy numbers. We found mul-
tiple copies of pfpm2 in 1.1% of isolates. All isolates carried 
K13 wild-type alleles (3D7-like), except 4 novel polymor-
phisms (Leu619Leu, Phe656Ile, Val666Val, Gly690Gly). 
Prevalence of isolates with pfcrt mutant (K76T) allele was 
low (2.3%). Prevalence of isolates with pfdhps mutant al-
leles (A437G and K540E) was >80%, indicating persistence 
of sulfadoxine/pyrimethamine resistance; however, markers 
of artemisinin were absent, and markers of piperaquine 
resistance were low. Piperaquine resistance isolates may 
spread in Mozambique as dihydroartemisinin/piperaquine 
drug pressure increases.
During the past decade, malaria control strategies have substantially reduced the malaria burden worldwide; 
several countries are advancing toward malaria elimina-
tion (1,2). A fundamental pillar for contributing to the re-
duction of the malaria burden has been artemisinin-based 
combination therapy. Unfortunately, the effectiveness of 
antimalarial drugs used for malaria treatment and chemo-
prevention during pregnancy has been threatened by the 
emergence of drug-resistant parasite populations (2–5).
The emergence of artemisinin resistance in Plas-
modium falciparum, with reduced in vivo susceptibility 
to artesunate, was reported in Southeast Asia (3,6). De-
tectable polymorphisms in the Kelch 13 (K13) propel-
ler domain in P. falciparum associated with artemisinin 
resistance have subsequently provided an additional tool 
for monitoring resistance to antimalarial drugs (7,8). In 
Cambodia, polymorphisms in the K13 propeller domain 
(mainly Y493H, R539T, I543T, and C580Y) were associ-
ated with in vitro prolonged parasite survival rates and 
in vivo delayed parasite clearance rates (8,9). Recently, 
plasmepsin 2 (pfpm2) copy number and pfcrt C101F 
polymorphism have been associated with piperaquine 
resistance (10–12). In addition, increased pfmdr1 cop-
ies have been associated with resistance to mefloquine 
(in vivo, in vitro, or both) and partially to lumefantrine 
(13–18). Specific point polymorphisms (at codons 86, 
184, 1034, 1042, and 1246) of the pfmdr1 gene have also 
been linked to resistance to antimalarial drugs (19,20). In 
field isolates tested in vitro as well as in laboratory lines, 
N86Y polymorphism was associated with chloroquine re-
sistance (21). Further, polymorphisms in the pfcrt gene 
have also been shown to affect parasite susceptibility to 
chloroquine (22), amodiaquine (23,24), and artemether/
lumefantrine (25). Recently, a nonsynonymous polymor-
phism in the pfcrt gene was shown to be prevalent in the 
genetic background of K13 mutant artemisinin-resistant 
isolates (26). In addition, polymorphisms in pfdhfr and 
pfdhps genes, specifically the quintuple mutant, includ-
ing the pfdhfr substitutions N51I, C59R, and S108N, as 
well as the pfdhps substitutions A437G and K540E, have 
been associated with a failure of sulfadoxine/pyrimeth-
amine treatment against uncomplicated P. falciparum 
malaria (27). In Africa, the pfdhps K540E polymorphism 
has been considered a useful epidemiologic marker of the 
quintuple mutations (28).
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Drug-Resistant Polymorphisms in P. falciparum 
The development of drug resistance could be influ-
enced by multiple factors such as polymorphism rate, fit-
ness costs, overall parasite load, strength of drug selection, 
treatment compliance, transmission intensity, host im-
munity, and erythrocyte disorders (29–31). Naturally ac-
quired immunity plays a major role in the emergence and 
clearance of artemisinin-resistant parasites (32). Because 
of increasing concern over the effectiveness of the nation-
ally recommended antimalarial drugs, the Mozambique 
Ministry of Health has made several changes in antima-
larial drug policy. In 2002, chloroquine monotherapy was 
replaced with sulfadoxine/pyrimethamine/amodiaquine as 
the first line of treatment against uncomplicated malaria 
(33); 2 years later, this combination was replaced with 
artesunate/sulfadoxine/pyrimethamine (33). In 2008, arte-
mether/lumefantrine was introduced to replace artesunate/
sulfadoxine/pyrimethamine (34). Molecular markers for 
antimalarial drug resistance have been considered useful 
for confirming parasite resistance, a major factor causing 
treatment failure. To determine whether parasites carrying 
these polymorphisms or gene amplifications exist in Mo-
zambique, we conducted molecular surveillance targeting 
K13, pfmdr1, pfcrt, and pfdhps polymorphisms and pfpm2 
and pfmdr1 copy numbers in field isolates collected from 4 
sentinel sites.
Materials and Methods
Study Sites and Population
We performed a descriptive observational study on blood 
samples collected before artemether/lumefantrine treatment 
(on day 0) in 2015 from 352 symptomatic children at 4 sen-
tinel sites in Mozambique (Figure 1): 1) Hospital Rural de 
Montepuez in Cabo Delgado Province (northern region), 2) 
Centro de Saúde de Dondo in Sofala Province (central re-
gion), 3) Hospital Provincial de Moatize in Tete Province 
(central region), and 4) Hospital Rural de Chokwe in Gaza 
Province (southern region). In Mozambique, transmission 
usually peaks during the rainy season (November–April). 
Transmission intensity in southern Mozambique is general-
ly low, although areas of high transmission may still occur 
(35). To determine molecular markers of drug resistance, we 
analyzed samples collected during a clinical trial conducted 
in 2015 (registration no. ACTRN12616001680459); the 
trial aimed to assess the efficacy and safety of artemether/
lumefantrine for treatment of uncomplicated P. falciparum 
malaria in children <5 years of age. The National Mozam-
bican Ethical Review Committee (Mozambique) and Hos-
pital Clínic (Barcelona, Spain) ethics review committees 
approved the study, and signed written informed consent 
was obtained from all participants’ guardian or parent.
Molecular Procedures
We extracted DNA from half of a 50-µL dried blood drop 
on Whatman 3-mm filter paper by using a QIAamp DNA 
Mini kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions. We used an ABI PRISM 7500 
HT Real-Time System (Applied Biosystems, Foster City, 
CA, USA) to amplify purified parasite DNA templates, fol-
lowing a previously described method (36,37). A standard 
curve was prepared from an in vitro culture of 3D7 strain 
containing known numbers of ring-infected erythrocytes. 
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Figure 1. Location of 
sampling sites and distribution 
of resistance markers of 
Plasmodium falciparum in 
Mozambique, 2015.
RESEARCH
The standard curve was run in triplicate for each test with 
5 serially diluted points. Parasitemia in the clinical samples 
was quantified by extrapolation against the standard curve.
To assess polymorphisms in the K13, pfcrt, pfmdr1, 
and pfdhps genes, we amplified purified DNA templates 
by using a 2720 Thermal Cycler (Applied Biosystems), 
following protocols described for K13 PCR (38) and pf-
crt PCR (35). To genotype polymorphisms in pfmdr1 and 
pfdhps genes, we designed new assays by using Sanger se-
quencing and restriction fragment length polymorphisms 
(online Technical Appendix, https://wwwnc.cdc.gov/EID/
article/24/1/17-0864-Techapp1.pdf). A total of 6 positive 
controls with known K13 alleles, provided by the Insti-
tut Pasteur in Cambodia, and 4 parasite lines (3D7, 7G8, 
Dd2, and V1/S) with known pfcrt and pfmdr1 alleles, avail-
able in the laboratory, were also processed, amplified, and 
sequenced at the same time as the studied samples (PCR 
characteristics in online Technical Appendix Table). To de-
termine the detection limit of Sanger sequencing, we used 
artificially mixed DNA samples of P. falciparum laboratory 
strains containing various known proportions of wild- and 
mutant-type alleles of pfcrt (K76T) and pfmdr1 (Y184F and 
S1034C) genes. To estimate polymorphism frequency, we 
considered isolates with mixed alleles to be mutated.
We assessed copy numbers of pfpm2 and pfmdr1 genes 
as described elsewhere (11) with minor changes (online 
Technical Appendix) by using quantitative PCR (qPCR). 
We performed amplification in 20-µL reaction mixtures for 
pfpm2, pfmdr1, and pfβ-tubulin genes, separately. We used 
the pfβ-tubulin gene as an endogenous control. All samples 
with estimated copy numbers >1.5 were defined as contain-
ing multiple copies and repeated for confirmation. The esti-
mated copy numbers were the average of the copy number 
of each clone in the isolate.
Data Analyses
We calculated the proportion of the mutant alleles and iso-
lates with multiple copies of pfpm2 and pfmdr1 genes on the 
basis of the number of samples with wild- and mutant-type 
alleles as well as isolates with single and multiple copies of 
the gene from P. falciparum isolates from each study site. 
To compare continuous data and categorical data between 
sites, respectively, we performed analyses of variance and 
χ2 tests. We defined statistical significance as p<0.05.
Results
Demographics and P. falciparum Infection
Among the 352 blood samples collected before arte-
mether/lumefantrine treatment (on day 0) during 2015, 
and followed up as part of the clinical trial, 351 (99.7%) 
were P. falciparum–infection positive according to 18Sr-
RNA qPCR. The mean (± SD) parasitemia (by qPCR) was 
100,229 ± 325,214 parasites/µL. Among participants, 159 
(45.2%) were female, mean (± SD) age was 2.8 ± 1.3 y, 
mean body temperature was 38.1 ± 1.1°C, and mean he-
moglobin level was 9.2 ± 1.9 g/dL. We also compared de-
mographic data and parasite densities according to study 
site (Table 1). Efficacy of artemether/lumefantrine in the 
in vivo study was high, and for nearly all patients (349 
[99.4%] of 351), parasitemia reverted to 0 in the first 3 
days; however, for 2 patients, parasites were still detect-
able by microscopy: 1 from Moatize (514 parasites/µL) and 
1 from Chokwe (3,763 parasites/µL). PCRs targeting msp1, 
msp2, and glurp genes were used to differentiate recru-
descence (same parasite strain) and reinfection (different 
parasite strain). We noted recrudescence of P. falciparum 
infections for 5 children (1 in Chokwe, 3 in Moatize, and 
1 in Montepuez) on days 21 and 28 after artemether/lume-
fantrine administration and reinfection for 7 children (3 in 
Moatize and 4 in Montepuez); 3 were reinfected on day 21 
and 4 on day 28 (39).
The polymorphism analyses of K13, pfmdr1, pfcrt, and 
pfdhps genes were successful for 98.3% to 100% isolates. 
Because no amplifications were noticed in negative con-
trols (with water and human genomic DNA), PCR assays 
were specific to P. falciparum genomic DNA only.
Detection Limit of Mixed Samples  
by Sanger Sequencing
We identified ¨A¨ alleles of pfcrt (K76T) and pfmdr1 
(Y184F) codons in artificially mixed samples by using 
Sanger sequencing when the proportion of target DNA was 
>10%. However, we identified ¨C¨ and ¨T¨ alleles of pfcrt 
(K76T) and pfmdr1 (Y184F) polymorphisms, respectively, 
in mixed samples when their proportion was >20% (on-
line Technical Appendix Figure 1). For pfmdr1 (S1034C) 
polymorphism, the minor allele was detected when its pro-
portion was >20% in a mixed sample (online Technical 
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Table 1. Characteristics of study participants with Plasmodium falciparum malaria, by site, Mozambique, 2015 
Characteristic Montepuez, n = 87 Dondo, n = 88 Moatize, n = 89 Chokwe, n = 88 p value 
Female, no. (%) 36 (41.4) 40 (45.5) 41 (46.1) 42 (47.7) 0.63 
Age, y, mean  SD 2.4  1.1 2.7  1.1 2.7  1.1 3.1  1.1 0.0002 
Temperature, °C, mean  SD 37.9  0.9 38.5  1.1 38.1  1.0 37.9  1.5 0.0043 
Parasite density, parasites/L, 
mean  SD* 
1.2  105  1.3  105 3.7  104  4.4  104 1.2  105  6.1  105 1.2  105  1.8  105 <0.0001 
Hemoglobin, g/dL, mean  SD 8.9 ± 2.2 8.7 ± 1.8 9.8 ± 1.7 9.2 ± 2.0 0.0018 
*By quantitative PCR. 
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Appendix Figure 1, panel C). For positive controls, we 
used several parasite lines with known K13, pfmdr1, and 
pfcrt alleles. As expected, sequencing analysis of all posi-
tive controls revealed wild- and mutant-type alleles of K13, 
pfmdr1, and pfcrt polymorphisms.
Copy Numbers for pfpm2 and pfmdr1
We successfully analyzed 351 (100%) samples for copy 
number variation in the pfpm2 and pfmdr1 genes. PCR ef-
ficiencies were 98.4% for pfpm2, 97.2% for pfmdr1, and 
99.2% for pfβ-tubulin genes. As expected, the estimated 
pfpm2 and pfmdr1 copy numbers for the positive controls 
were 3–4 copies. The estimated mean (interquartile range) 
copy numbers were 3.51 (3.37–3.62) for pfpm2 and 3.62 
(3.51–3.79) for pfmdr1 positive controls. When we used 
a copy number threshold of 1.5 to define multiple copies, 
only 4 (1.1%) and 5 (1.4%) of the 351 isolates had mul-
tiple copies of pfpm2 and pfmdr1, respectively (Table 2; 
Figure 2). The range of estimated pfpm2 copy numbers 
was 0.59–1.79 and of pfmdr1 was 0.58–1.88. The copy 
number of pfpm2 and pfmdr1 genes did not significantly 
differ between isolates from different sites. The proportion 
of isolates with multiple copies of the pfpm2 gene was the 
highest at Chokwe (2 [2.3%] of 87). Only 1 (1.1%) of 88 
samples from Dondo had multiple copies of pfpm2 and 
pfmdr1 genes.
K13 Polymorphisms
We successfully achieved K13 PCR and sequencing 
for all 351 isolates. None of the isolates analyzed con-
tained the polymorphisms most frequently found in 
isolates from Cambodia (8). However, we observed 4 
novel polymorphisms at nt 1725147 (codon 619; 0.28% 
[1/351]); 1725032 (codon 656; 0.28% [1/351]); 1725000 
(codon 666; 0.57% [2/351]); and 1724927 (codon 690; 
0.85% [3/351]) of the K13 gene. All polymorphisms 
were synonymous except for 1 at codon 656, which led 
to a change from phenylalanine to isoleucine. When we 
compared frequencies of new polymorphisms between 
sites, we found no significant differences. We also ob-
served the polymorphism Cys469Cys, previously de-
scribed in P. falciparum field isolates from Ghana (40), 
in 3 (0.85%) of the 351 isolates. Isolates from patients 
with parasitemia on day 3 and recrudescence contained 
wild-type K13 gene polymorphisms.
pfcrt Polymorphisms
We successfully amplified all 351 samples for pfcrt and 
sequenced the amplification products; mutant alleles were 
found at codons M74I, N75E, and K76T only in 8 (2.3%) 
samples. The mutant alleles (M74I, N75E, and K76T) 
were present only in isolates collected from Chokwe (8 
[9.2%] of 87). When we compared frequencies of mu-
tant alleles between sites, the difference was significant 
(p<0.0001). In the studied isolates, the mutant (F) allele 
at codon 101 was absent. Isolates from patients with para-
sitemia on day 3 and recrudescence contained wild-type 
pfcrt gene polymorphisms.
pfmdr1 Polymorphisms
We successfully amplified and sequenced pfmdr1_f1 for 351 
(100%) samples and pfmdr1_f2 fragments for 350 (99.7%) 
samples. We identified 15 polymorphisms all across the 
pfmdr1 gene, including 5 (33.3%) with nonsynonymous 
polymorphisms and 10 (66.7%) with synonymous poly-
morphisms. Among nonsynonymous polymorphisms, 3 
(T1192A, F1194S, and Y1197N) were newly identified and 
2 (N86Y and Y184F) had been previously reported (41). 
Among synonymous polymorphisms, 7 (L1030L, D1061D, 
D1127D, S1137S, L1174L, D1179D, and N1189N) were 
newly identified and 3 (G102G, G182G, and T1069T) had 
been previously reported (41). Among the 351 isolates, 
we found 11 (3.1%) N86Y and 164 (46.7%) Y184F mu-
tant alleles (Table 3). All newly identified nonsynonymous 
mutant alleles were present only once, except for Y1197N, 
which was found twice (0.6% [2/350]). The frequency of 
polymorphisms (N86Y and D1179D) differed significantly 
between isolates from the 4 sites (Table 3). The propor-
tion of N86Y and D1179D polymorphisms was highest in 
isolates from Chokwe. We observed none of the other most 
frequent polymorphisms (S1034C, N1042D, and D1246Y) 
of the pfmdr1 gene among the analyzed samples. Isolates 
from patients with parasitemia on day 3 and recrudescence 
contained wild-type pfmdr1 gene polymorphisms.
pfdhps Polymorphisms
Polymorphism analysis by PCR followed by sequencing 
for S436F and A437G polymorphisms was successful for 
345 (98.3%) samples and analysis by PCR–restricted frag-
ment length polymorphism for K540E polymorphism for 
348 (99.1%) samples. Among all isolates, 10 (2.9%) of 345 
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Table 2. Plasmodium falciparum isolates with increased pfpm2 and pfmdr1 gene copy numbers, 4 sentinel sites, Mozambique, 2015 
Site 
pfpm2  pfmdr1 
No. (%) 
Mean  SD 
No. (%) 
Mean  SD <1.2 1.2–1.5 >1.5 <1.2 1.2–1.5 >1.5 
Montepuez, n = 87 82 (94.3) 5 (5.7) 0 0.85  0.2  87 (100.0) 0 0 0.93  0.1 
Dondo, n = 88 66 (75.0) 21 (23.9) 1 (1.1) 1.02  0.2  68 (77.3) 18 (20.4) 2 (2.3) 0.99  0.3 
Moatize, n = 89 73 (82.0) 15 (16.9) 1 (1.1) 1.01  0.2  81 (91.0) 7 (7.9) 1 (1.1) 0.99  0.2 
Chokwe, n = 87 77 (88.5) 8 (9.2) 2 (2.3) 0.94  0.2  70 (80.5) 15 (17.2) 2 (2.3) 0.98  0.2 
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contained S436F, 289 (83.8%) of 345 contained A437G, 
and 286 (82.2%) of 348 contained K540E mutant alleles. 
At codon 436, we also found 3 mutant alleles: S436C 
(0.9%), S436A (4.9%), and S436H (0.6%). When we com-
pared frequencies of 3 single-nucleotide polymorphisms at 
different sites, we noted significant differences (Table 4). 
The proportion of isolates with A437G and K540E poly-
morphisms was the highest at Moatize, and the proportion 
with S436F, S436C, S436A, and S436H alleles was highest 
at Montepuez.
Discussion
We provide evidence for the presence of multiple cop-
ies of pfpm2 in 4 (1.1%) of 351 P. falciparum isolates 
circulating in southern Mozambique despite the absence 
of piperaquine drug pressure. Thus, with adequate drug 
pressure, isolates resistant to piperaquine may spread in 
Mozambique, as occurred in Southeast Asia (10,42,43). 
In selected areas of Cambodia in 2008, piperaquine was 
introduced as a partner drug of artemisinin (44). Soon af-
ter its introduction, as early as 2010, piperaquine resis-
tance in western Cambodia emerged at an alarming rate 
(45). Subsequent reports confirmed a rapid increase in 
failure of dihydroartemisinin/piperaquine in other parts 
of Cambodia (42,46,47). The most frequent K13 mutants 
associated with artemisinin resistance were absent in 
the isolates from Mozambique. We also determined that 
prevalence of pfcrt (K76T) and pfmdr1 (N86Y) markers 
of resistance are low, supporting previous evidence for 
the return of parasites carrying pfcrt wild-type alleles in 
Mozambique (35), in contrast to persistence of pfdhps 
(A437G [83.8%]) and K540E [82.2%]) polymorphisms, 
markers of sulfadoxine/pyrimethamine resistance (34). 
The well-characterized polymorphism in pfmdr1 (Y184F 
[46.7%]) was also prevalent in Mozambique.
We found very low prevalence (<1%) for 4 new poly-
morphisms (Leu619Leu, Phe656Ile, Val666Val, and Gly-
690Gly) in the K13 gene of P. falciparum isolates from 
Mozambique. All polymorphisms except Phe656Ile were 
synonymous. Previously, V494I K13 nonsynonymous 
polymorphism has also been reported in Mozambique 
(48). In Africa, K13 nonsynonymous polymorphisms 
have also been reported at low frequencies in isolates 
from Cameroon, Central African Republic, Democratic 
Republic of the Congo, Gabon, The Gambia, Kenya, Mad-
agascar, Malawi, Mali, Rwanda, Togo, Uganda, Zambia, 
and Equatorial Guinea (38,40,49–50; references 51,52 in 
online Technical Appendix). The association of nonsyn-
onymous polymorphisms with delayed parasite clearance 
has only recently been identified in Africa (reference 52 
in online Technical Appendix).
Resistance to both chloroquine and amodiaquine has 
been mainly associated with a single K76T mutant al-
lele in the pfcrt gene (22–24). In our study, its prevalence 
in 8 (2.3%) of 351 samples was significantly lower than 
that found in previous studies in Mozambique (33,34; 
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Figure 2. pfpm2 and pfmdr1 
copy numbers of Plasmodium 
falciparum isolates from 4 
sentinel sites, Mozambique, 
2015. Multiple copies of pfpm2 
and pfmdr1 genes have been 
associated with resistance to 
piperaquine and mefloquine, 
respectively.
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reference 53 in online Technical Appendix). Our pfcrt data 
align with previous evidence for the return of parasites car-
rying pfcrt wild-type alleles in Mozambique (35) and in 
other countries in Africa, such as Ethiopia (reference 54 in 
online Technical Appendix), Malawi (reference 55 in on-
line Technical Appendix), and Cameroon (reference 56 in 
online Technical Appendix). The selective disadvantage of 
mutant parasites in the absence of drug pressure has been 
proposed as the leading factor contributing to the reemer-
gence of chloroquine-susceptible parasites (reference 57 in 
online Technical Appendix). Because artemether/lumefan-
trine has been shown to select for the wild-type pfcrt 76K 
allele (25), this reemergence might be accelerated because 
of the increased use of artemether/lumefantrine as a first-
line treatment for uncomplicated malaria in Mozambique 
(reference 53 in online Technical Appendix). 
Our study also provides evidence for the presence 
of few P. falciparum isolates with multiple copies of the 
pfmdr1 gene (5 [1.4%] of 351) circulating in southern 
Mozambique (34). Increased pfmdr1 copies have been 
associated with resistance to mefloquine and partial re-
sistance to lumefantrine (13–18). Our study found that 
prevalence of the pfmdr1 N86Y mutant allele has de-
creased and the Y184F mutant allele has increased over 
time, in contrast with findings of other studies from Mo-
zambique (34; references 55,58 in online Technical Ap-
pendix). We identified 10 new polymorphisms (L1030L, 
D1061D, D1127D, S1137S, L1174L, D1179D, N1189N, 
T1192A, F1194S, and Y1197N) that had not been pre-
viously described for the pfmdr1 gene. Among the 15 
polymorphisms identified in the pfmdr1 gene, we ob-
served significant differences between sites for the N86Y 
and D1179D polymorphisms only.
Of 351 children who had received adequate treatment 
with artemether/lumefantrine (6 doses), 2 were still posi-
tive for parasitemia on day 3 (39). These isolates contained 
wild-type K13 gene polymorphisms. P. falciparum–posi-
tive patients for whom artemether/lumefantrine treatment 
failed had parasites that carried wild-type pfcrt and pfmdr1 
polymorphisms. This observation suggests that in vivo 
artemether/lumefantrine resistance may be caused not only 
by variations in the pfcrt and pfmdr1 genes but possibly 
by parasite selection of variations in other genes; however, 
drug bioavailability issues may also have contributed.
A high proportion of the P. falciparum isolates from 
Mozambique contained K540E (82.2%) and A437G 
(83.8%) mutant alleles. These mutant alleles may still 
not jeopardize the effectiveness of sulfadoxine/pyrimeth-
amine for malaria prevention in Mozambique; recent 
findings suggest that only >90% prevalence of a pfdhps 
K540E polymorphism could reduce the effectiveness of 
intermittent preventive therapy to clear peripheral para-
sites and prevent new infections during pregnancy (refer-
ence 59 in online Technical Appendix). Therefore, sulfa-
doxine/pyrimethamine remains effective for intermittent 
preventive therapy during pregnancy, despite the high 
frequency of quintuple mutants; thus, the World Health 
Organization continues to recommend the use of intermit-
tent preventive therapy to prevent malaria during preg-
nancy (references 60–62 in online Technical Appendix). 
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Table 3. Distribution of Plasmodium falciparum pfmdr1 polymorphism (mutated allele) frequencies among 4 sentinel sites, 
Mozambique, 2015* 
SNP Montepuez, no. (%) Chokwe, no. (%) Moatize, no. (%) Dondo, no. (%) p value 
N86Y 1 (1.1) 6 (6.9) 0 4 (4.5) 0.03 
G102G 1 (1.1) 2 (2.3) 2 (2.2) 1 (1.1) 0.88 
G182G 4 (4.6) 1 (1.1) 3 (3.4) 1 (1.1) 0.37 
Y184F 45 (51.7) 39 (44.8) 42 (47.2) 38 (43.2) 0.69 
L1030L 0 0 1 (1.1) 0 0.40 
D1061D 0 1 (1.1) 0 0 0.40 
T1069T 10 (11.5) 5 (5.7) 4 (4.5) 8 (9.2) 0.28 
D1127D 1 (1.1) 0 2 (2.2) 0 0.30 
S1137S 2 (2.3) 0 0 2 (2.3) 0.25 
L1174L 1 (1.1) 0 0 0 0.40 
D1179D 0 9 (10.3) 2 (2.2) 0 0.0001 
N1189N 0 0 1 (1.1) 1 (1.1) 0.57 
T1192A 0 1 (1.1) 0 0 0.40 
F1194S 1 (1.1) 0 0 0 0.40 
Y1197N 1 (1.1) 0 0 1 (1.1) 0.57 
*SNP, single-nucleotide polymorphism. 
 
 
Table 4. Distribution of Plasmodium falciparum pfdhps gene polymorphism (mutated allele) frequencies among 4 sentinel sites, 
Mozambique, 2015* 
SNP Montepuez, no. (%) Chokwe, no. (%) Moatize, no. (%) Dondo, no. (%) p value 
S436F/C/A/H 30 (34.5) 2 (2.4) 0 0 <0.0001 
A437G 51 (58.6) 79 (94.1) 82 (93.2) 77 (89.5) <0.0001 
K540E 50 (57.5) 77 (90.6) 83 (93.3) 76 (87.4) <0.0001 
A437G + K540E 47 (54.1) 77 (91.7) 80 (90.9) 76 (88.4) <0.0001 
*SNP, single-nucleotide polymorphism. 
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However, alternative antimalarial drugs for intermittent 
preventive therapy during pregnancy are needed because 
the prevalence of the K540E polymorphism in Mozam-
bique is close to the threshold.
In conclusion, we report that prevalence of isolates 
with multiple copies of pfpm2 is lower than that found 
by previous studies in Cambodia (34.3%) and Vietnam 
(54.3%) (10,43), and we report the absence of K13 poly-
morphisms known to be associated with artemisinin resis-
tance. We also report the return of parasites carrying pfcrt 
wild-type alleles (except in Chokwe) and persistence of 
parasites with pfdhps mutations associated with sulfadox-
ine/pyrimethamine resistance in Mozambique. Sulfadox-
ine/pyrimethamine–resistant isolates may be maintained by 
the constant use of intermittent preventive therapy during 
pregnancy, use of drug outside of hospitals, the very com-
mon use of co-trimoxazole (as prophylaxis for HIV-infect-
ed persons), and the low fitness cost of the polymorphisms 
(33; references 63,64 in online Technical Appendix). In 
contrast, the fitness cost of the pfcrt mutant allele seems 
to be high, probably accounting for the return of parasites 
carrying pfcrt wild-type alleles in Mozambique (reference 
57 in online Technical Appendix). Current regional elimi-
nation efforts, as part of the G8 Malaria Elimination Ini-
tiative, may lead to more aggressive strategies involving 
population-wide distribution of antimalarial drugs, such as 
dihydroartemisinin/piperaquine, resulting in significantly 
increased drug pressure. Our findings might provide base-
line prevalence data that enable us to directly determine the 
effects that increasing malaria control efforts or elimination 
programs will have on resistance evolution.
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EBOLA: People + Public Health + Political Will  is an investigation of the historic 2014–16 
Ebola Fever Virus epidemic in West Africa, the United States, and around the world. As the 
crisis unfolded in Guinea, Liberia, and Sierra Leone in 2014, it evolved into both a health and 
humanitarian crisis. When it became clear that Ebola could potentially spread exponentially, 
threatening global health security, there was a coordinated, massive response.
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